User profiles for Theerada Assawasaksakul

Theerada Assawasaksakul

Rheumatologist, Chulalongkorn University, King Chulalongkorn Memorial Hospital
Verified email at chula.ac.th
Cited by 104

[HTML][HTML] A comparative study of conventional cytology and cell block method in the diagnosis of pleural effusion

T Assawasaksakul, V Boonsarngsuk… - Journal of thoracic …, 2017 - ncbi.nlm.nih.gov
Background In a patient with pleural effusion, cytological study (CS) is one of the most useful
investigations, especially when malignancy is suspected. Instead of applying only CS, the …

[HTML][HTML] Comparison of immunogenicity and safety of inactivated, adenovirus-vectored, and heterologous adenovirus-vectored/mRNA vaccines in patients with …

T Assawasaksakul, T Lertussavavivat… - Vaccines, 2022 - mdpi.com
Background: Impaired immune responses to COVID-19 vaccines have been observed in
autoimmune rheumatic disease patients. Determining the most effective and safe vaccine …

Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid …

T Assawasaksakul, S Sathitratanacheewin… - Lupus Science & …, 2022 - lupus.bmj.com
Objectives To evaluate the safety and immunogenicity of third and fourth BNT162b2 boosters
in patients with SLE and rheumatoid arthritis (RA). Methods Patients with SLE and RA …

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: A case series

T Assawasaksakul, S Sathitratanacheewin… - RMD open, 2021 - rmdopen.bmj.com
Since the COVID-19 pandemic, CoronaVac, an inactivated SARS-CoV-2 vaccine, has been
widely deployed in several countries for emergency use. However, the immunogenicity of …

Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in systemic lupus erythematosus and …

T Assawasaksakul, S Sathitratanacheewin… - medRxiv, 2022 - medrxiv.org
Objectives To evaluate the safety and immunogenicity of third and fourth BNT162b2 boosters
in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients. Methods …

Urine γ-interferon-inducible protein (IP-10) as a biomarker of histological activity of lupus nephritis

…, C Promjean, TB Suttichet, T Assawasaksakul… - medRxiv, 2022 - medrxiv.org
Introduction Conventional markers are not reliable predictors of histological activity of lupus
nephritis (LN). We aimed to examine the utility of urine γ-interferon-inducible protein (IP-10) …

[HTML][HTML] Clinical case: Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients …

T Assawasaksakul, S Sathitratanacheewin… - RMD …, 2021 - ncbi.nlm.nih.gov
Since the COVID-19 pandemic, CoronaVac, an inactivated SARS-CoV-2 vaccine, has been
widely deployed in several countries for emergency use. However, the immunogenicity of …

Effects of intradialytic cycling exercise on daily physical activity, physical fitness, body composition, and clinical parameters in high-volume online hemodiafiltration …

N Assawasaksakul, W Sirichana, W Joosri… - … Urology and Nephrology, 2021 - Springer
Purpose The mortality of dialysis patients treated with high-volume online hemodiafiltration (OL-HDF)
is better than hemodialysis, but is still higher than healthy population. Low daily …

[PDF][PDF] Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with …

T Assawasaksakul, T Lertussavavivat… - 2022 - academia.edu
Background: Impaired immune responses to COVID-19 vaccines have been observed in
autoimmune rheumatic disease patients. Determining the most effective and safe vaccine …

[PDF][PDF] Morphological Evaluation Of The Diagnostic Efficacy Of Cytological Smear Technique Versus Cell Block Method In The Cytology Of Body Fluids

M Agnihotri - ijlbpr.com
… by Theerada Assawasaksakul et al. Out of a total of 353 samples, the final diagnoses included
278 (78.8%) malignancies, 41 (11.6%) infectious diseases, 16 (4.5%) other inflammatory …